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Mitochondria dynamics
Microtubule networkIn Parkinson's disease mitochondrial dysfunction can lead to a deﬁcient ATP supply to microtubule protein
motors leading to mitochondrial axonal transport disruption. Compromised axonal transport will then lead to
a disorganized distribution ofmitochondria and other organelles in the cell, aswell as, the accumulation of aggre-
gated proteins like alpha-synuclein. Moreover, axonal transport disruption can trigger synaptic accumulation of
autophagosomes packed with damaged mitochondria and protein aggregates promoting synaptic failure.
Wepreviously observed that neuronal-like cells with an inherentmitochondrial impairment derived fromPDpa-
tients contain a disorganized microtubule network, as well as, alpha-synuclein oligomer accumulation. In this
work we provide new evidence that an agent that promotes microtubule network assembly, NAP (davunetide),
improvesmicrotubule-dependent trafﬁc, restores the autophagicﬂux and potentiates autophagosome–lysosome
fusion leading to autophagic vacuole clearance in Parkinson's disease cells.Moreover, NAP is capable of efﬁciently
reducing alpha-synuclein oligomer content and its sequestration by the mitochondria. Most interestingly, NAP
decreasesmitochondrial ubiquitination levels, aswell as, increasesmitochondrialmembrane potential indicating
a rescue in mitochondrial function.
Overall, we demonstrate that by improving microtubule-mediated trafﬁc, we can avoid mitochondrial-induced
damage and thus recover cell homeostasis. These results prove that NAP may be a promising therapeutic lead
candidate for neurodegenerative diseases that involve axonal transport failure and mitochondrial impairment
as hallmarks, like Parkinson's disease and related disorders.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
There is accumulating evidence from in vitro and in vivo studies sug-
gesting that mitochondrial abnormalities are a common event in spo-
radic Parkinson's disease (sPD) [1–4]. Moreover, defects in axonal and
dendritic transport have also been linked to various neurodegenerative
processes, including sPD pathogenesis. Indeed, sPD is characterized by a
sequence of neuropathological events that arise due to a dying-back
pattern of neuronal degeneration, namely early loss of synaptic termi-
nals and axonopathy, before cell death [5–8]. Another central hallmark
of PD is the presence of intracytoplasmatic aggregates, named Lewy
Bodies that are mainly composed of alpha-synuclein (ASYN). Several
studies suggest that larger ASYN aggregates may have reduced toxicitysynuclein; CT cybrids, (control
brids); mtDNA, mitochondrial
ﬁc Ofﬁcer at Allon Therapeutics
nce and Cell Biology, University
bra, Portugal. Tel.: +351 239
rdoso).
ights reserved.relative to their smaller-sized counterparts, the soluble oligomers
[9–12]. ASYN inclusion dynamics results from an intricate process that
may distress axonal transport, autophagic-lysosomal and ubiquitin-
proteasome pathways.
Mitochondrial function and axonal transport are intimately connect-
ed. Mitochondria supply the energy for cytoskeleton motor proteins to
transport them along cytoskeleton tracks to areas in the cell where en-
ergy demands are high and calciumbuffering is required [13,14]. Impor-
tantly, alteration in microtubule dynamic may lead to a defective trafﬁc
ofmitochondria inside the cell contributing ultimately to its dysfunction
and to the disruption of protein transport, such as ASYN. ASYN, which is
normally transported by fast axonal transport, can then accumulate po-
tentiating the disruption of intracellular trafﬁcking [15].
Sincemitochondria aremetabolically and functionally compromised
in PD tissues it is important to evaluate mitochondrial contribution
to microtubule transport failure. Axonal transport requires energy to
allow molecular motors to move along microtubules and transport mi-
tochondria, autophagic and synaptic vesicles [16]. Recently, Zala and co-
workers [17] challenged the assumption that mitochondrial ATP was
the principal source of energy for motor molecules. They showed that
the transport of BDNF carrying vesicles was not affected by the inhibi-
tion of mitochondrial ATP production, but failed to demonstrate the
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of mitochondrial ATP by molecular motors.
In previous work we observed that sPD cybrids contain mito-
chondrial abnormalities, such as a complex I defect and ATP depletion
[18–20]. This ex-vivo model results from the fusion of teratocarcino-
ma (NT2) cells that were depleted from their mitochondrial DNA
(mtDNA) (NT2 rho0) with mitochondria isolated from platelets of
age-matched healthy individuals or PD patients. Indeed, we and others
claim that the differences observed in the mitochondrial pool between
CT and PD cybrids are due to mtDNA variations. Although we agree
that there is no demonstrated homoplasmicmtDNAmutation that asso-
ciates with PD, we cannot rule out the presence of low abundance
heteroplasmic mutations, epigenetic modiﬁcations to the mtDNA, or
the possibility that polymorphic variation (rather than mutations per
se) is responsible for the observed biochemical phenotypes. mtDNA
polymorphic variation between individuals is high, which suggests
that mtDNA between cybrid lines containing mtDNA from different in-
dividuals is certainly different. The great potential of this model is that
these cells possess the same nuclear background but different mito-
chondrial background therefore allowing us to study mitochondrial
role in several cellular pathways [21]. We also demonstrated that sPD
cybrids present basal microtubule disruption with a concomitant accu-
mulation of ASYN oligomers [22]. Hence, we showed that microtubule
network alterations are due to mitochondrial deﬁcits. We further
proved that taxol, a known microtubule stabilizer, promoted microtu-
bule network assembly and a decrease in ASYN oligomer content [22].
However, taxol is not neuron-speciﬁc, has limited brain bioavailability
and in high concentration has the capacity to inhibit microtubule
dynamics [23]. Thus, more speciﬁc, brain-penetrable microtubule-
interacting drugs are required [24]. Herein, we decided to use a peptide
known as NAP (davunetide) that is an eight amino acid peptide derived
from an activity-dependent neuroprotective protein [25–27]. This pep-
tide associates with tubulin and enhances propermicrotubule assembly
[28–30].We demonstrate that the alterations induced bymitochondrial
deﬁcits on microtubule assembly and microtubule-mediated trafﬁc in
sPD cybrids are prevented by NAP. Correlated with this we observed
that NAP promoted autophagic vacuole clearance by increasing autoph-
agic ﬂux and autophagosome–lysosome fusion in PD cells. Moreover,
NAP restored mitochondrial distribution and mitochondrial membrane
potential and was able to prevent the accumulation of Triton-soluble
and insoluble ASYN oligomeric species in sPD cybrids.
Taken collectively, our results provide strong data that NAP is a
promising therapeutic agent in the PD treatment.
2. Material and methods
2.1. Chemicals
Nocodazole, MPP+ (1-methyl-4-phenylpyridinium), ammoni-
um chloride (NH4Cl), leupeptin, oligomycin, carbonyl cyanide-p-
triﬂuoromethoxyphenylhydrazone (FCCP), rapamycin, ubiquinone
and rotenonewere obtained from Sigma (St. Louis, MO, USA). Rhoda-
mine 123 was purchased from Molecular Probes (Eugene, OR, USA).
NAP was generously donated by Dr. Illana Gozes from Tel Aviv
University.
2.2. Human subjects
Subject participation was approved by the University of Kansas
School of Medicine's Institutional Review Board. The mean age of the
PD subjects (n=9) who participated in this study was 64±12.8years,
and for the control subjects (n=5) it was 74.3±5.5years (Supplemen-
tary Table I). The PD subjects were followed regularly in a tertiary refer-
ral movement disorders clinic at the Kansas University Medical Center
and met current criteria used to diagnose idiopathic PD in clinical and
research settings [31]. The control subjects were participants of alongitudinal “normal aging” cohort that is characterized serially by the
Brain Aging Program at the University of Kansas School of Medicine
(see Supplementary Table I). After obtaining informed consent, sporad-
ic PD and age-matched control subjects underwent a 10 ml or 60 ml
phlebotomy using tubes containing acid-citrate-dextrose as an antico-
agulant. The control subjects had no evidence of a neurodegenerative
condition.
2.3. Preparation of platelet mitochondria
Following provision of informed consent, 60 ml of blood was
collected through venipuncture in tubes containing acid–citrate–
dextrose as an anticoagulant. Mitochondria were obtained from
human platelets according to previously described methods [32].
Platelet mitochondrion protein concentrations were measured by the
Bradford protein assay [33], in which bovine serum albumin was used
as the standard.
2.4. Creation of cybrid cell lines
To create the cybrid cell lines for this study, we used NT2 (Ntera2/
D1) cells, a teratocarcinoma cell line with neuronal characteristics
(Stratagene, La Jolla, CA) [34,35]. These cells were depleted of endoge-
nous mtDNA (NT2 rho0 cells) via long-term ethidium bromide expo-
sure [36,37]. NT2 rho0 cells lack intact mtDNA, do not possess a
functional electron transport chain, and are auxotrophic for pyruvate
and uridine [38]. Consequently, platelet mitochondria from either PD
or control subjects were isolated from the individual blood samples
and were used to repopulate NT2 rho0 cells with mtDNA as previously
described [36,37]. We generate control and disease cell lines at the
same point in time and only compared a disease serieswith a control se-
ries that had beenmade at the same time andwith the same immediate
stock of NT2 rho0 cells. Brieﬂy, NT2 rho0 cells were co-incubated in
polyethylene glycol (Merck Chemicals) with platelets from the human
subjects [38]. After that the resultingmixture was grown in Rho0medi-
um in T75 ﬂasks. Seven days after plating, untransformed cells were re-
moved bywithdrawal of pyruvate and uridine from the culturemedium
and substitution of dialyzed, heat inactivated fetal calf serum for non-
dialyzed, heat inactivated fetal calf serum [39,21]. Maintaining cells in
selection medium removes rho0 cells that have not repopulated with
platelet mtDNA. Moreover, “mock fusions” in which NT2 rho0 cells
were not incubated with platelets were plated andmaintained in selec-
tionmedium in parallel with the true fusions. During the selection peri-
od all cells from themock fusions died. After selectionwas complete, the
resultant cybrid cells were switched to cybrid growth medium. Cells
were grown in 75 cm2 tissue culture ﬂasks maintained in a humidiﬁed
incubator at 37 °C and 5% CO2.
2.5. Cell line culture and experimental treatments
Optimem and Dulbeco's modiﬁed Eagle's medium (DMEM) were ob-
tained from Gibco-Invitrogen (Life Technologies Ltd, UK). Non-dialyzed
and dialyzed Fetal Bovine Serum (FBS) was obtained from Gibco-
Invitrogen (Life Technologies Ltd, UK). NT2 rho0 cell growth medium
Optimemwas supplemented with 10% non-dialyzed FBS, 200μg/ml so-
dium pyruvate from Sigma (St. Louis, MO, USA), 100μg/ml uridine from
Sigma (St. Louis, MO, USA) and 1% penicillin–streptomycin solution.
NT2 cybrid selection medium consisted of DMEM supplemented with
10% dialyzed FBS and 1% penicillin–streptomycin solution. Cybrid
growth medium consisted of Optimem supplemented with 10% non-
dialyzed FBS and 1% penicillin–streptomycin solution. Prior to experi-
ments, cell lines were maintained in the cybrid growth medium. For
Western blotting analysis andmitochondrial respiratory chain complex
I activity, cybrid cell lines were seeded in petri-dishes at a density of
0.5 × 106 cells/well. For immunoblotting analysis, cybrid cell lines
were grown on coverslips in 12-well plates at a density of 0.1 × 106
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μ-slide 8-well plates from ibidi at a density of 0.06×106 cells/well. For
mitochondrial membrane potential measurements, cybrid cell lines
were grown on 24-well plates at a density of 0.075 × 106 cells/well.
After 24h, experimental treatmentswere performed.NAPwas prepared
inwater andwas added for 24h to the culturemediumwith a ﬁnal con-
centration of 1 nM. Where indicated, 0.5 μM rapamycin, 20mM NH4Cl
and/or 100 μM leupeptin (Sigma, St. Louis, MO, USA), were added for
4 h to the culture medium. The combination of NH4Cl with leupeptin
blocks all types of autophagy, as it reduces the activity of all lysosomal
proteases by increasing the lysosomal lumen pH without affecting the
activity of other intracellular proteolysis systems [40]. Rapamycin is
an mTOR inhibitor that induces autophagy.
2.6. Animals
Experiments involving animals were approved by and performed in
accordance with the University of Coimbra Institutional Animal Care
and Use Committee Guidelines and European Community Council
Directive for the Care and Use of Laboratory Animals (86/609/ECC).
2.7. Primary cortical neuronal cultures and experimental treatments
Neurobasal medium and B27 supplement were purchased from
Gibco BRL, Life Technologies (Scotland, UK). Trypsin, trypsin inhibitor
type II-S-soybean and bovine serum albumin (BSA) were obtained
from Sigma (St. Louis, MO, USA). Primary cultures of cortical neurons
were prepared from 15 to 16day embryos of Wistar rats according to
the method described by Yu and collaborators [41], with some mod-
iﬁcations [42]. Brieﬂy, removed cortices were aseptically dissected
and placed in Ca2+ and Mg2+-free Krebs buffer: 120.9 mM NaCl,
4.8 mM KCl, 1.2 mM KH2PO4, 13 mM glucose and 10 mM HEPES
(pH 7.4) supplemented with BSA (0.3 mg/mL). Cortical tissues were
then washed and incubated in Krebs solution supplemented with
BSA, and containing trypsin (0.35mg/mL) for 10min at 37 °C. The tis-
sue digestion was subsequently stopped with the addition of Krebs
buffer containing trypsin inhibitor (type II-S) (0.75mg/mL), followed
by a centrifugation at 140×g for 5min. After washing the pellet once
with Krebs buffer, the cells were resuspended in fresh neurobasal medi-
um supplemented with 0.2 mM L-glutamine, 2% (v/v) B27 supplement,
penicillin (100U/mL) and streptomycin (100μg/mL) andweredissociated
mechanically. ForWestern Blotting analysis cortical neuronswere seeded
on poly-L-lysine (0.1 mg/mL) coated 6-well plates at a density of
1.6 × 106 cells/mL. For immunoblotting analysis, cortical neurons were
seeded on poly-L-lysine (0.1 mg/mL) coated coverslips at a density of
0.75 × 106 cells/mL. The cultures were maintained in serum-free
neurobasal medium supplemented with B27, at 37°C in a humidiﬁed
atmosphere of 5% CO2 and atmosphere of 5% CO2/95% air for 5–7days
before treatments in order to allow neuronal differentiation. After 5 to
7 days in vitro, cells were incubated for 24 h with MPP+ (Sigma, St.
Louis, MO, USA) freshly prepared in water with a ﬁnal concentration
of 100 μM and when indicated with NAP prepared in water with
a ﬁnal concentration of 10 nM. In autophagic ﬂux experiments
20 mM NH4Cl and 20 μM leupeptin (Sigma, St. Louis, MO, USA),
were added 4 h before the NAP and/or MPP+ treatment ended. For
all experimental procedures, controls were performed in the absence
of those agents.
2.8. Preparation of cell extracts containing soluble and polymeric tubulin
To prepare the soluble and polymeric fractions of cell tubulin, cells
were washed twice very gently with a microtubule stabilizing buffer
(0.1MN-morpholinoethanesulfonic acid, pH 6.75, 1mM MgSO4, 2mM
EGTA, 0.1mM EDTA, 4M glycerol). Soluble proteins were extracted at
37 °C for 6 min in 100 μL of microtubule stabilizing buffer containing
1% Triton X-100. The remaining fraction in the culture dish wasscrapped in 100 μL of 25mM Tris (pH 6.8), 0.1% SDS, and frozen three
times in liquid nitrogen [43]. Proteinwas quantiﬁed by the Bio-Rad pro-
tein dye assay reagent (Bio-Rad, Hercules, CA, USA).2.9. Preparation of mitochondrial and cytosolic extracts
To performmitochondrial and cytosolic fractions, cells were washed
with phosphate-buffered solution (PBS), scraped in a buffer containing
250mM sucrose, 20mMHepes, 1mMEDTA, 1mMEGTA, supplemented
with protease inhibitors (0.1 M phenyl-methylsulfonyl ﬂuoride —
PMSF) from Sigma (St. Louis, MO, USA), 0.2 M dithiothreitol (DTT)
from Sigma (St. Louis, MO, USA), and 1:1000 dilution of a protease in-
hibitor cocktail and subsequently homogenized. Then cells are centri-
fuged at 492 ×g for 12 min at 4 °C. The resulting supernatant was
centrifuged at 11,431 ×g for 20min at 4 °C. Pellets resulting from this
step constitute a crude mitochondrial fraction and the supernatants
corresponded to the cytosolic fraction. The cytosolic fraction was then
precipitated with TCA 5% and consequently centrifuged at 15,643 ×g
for 10min at 4°C. The resulting pellet was resuspended in sucrose buffer
and was then neutralized with 2.5M KOH pH7. Subsequently cytosolic
andmitochondrial fractions were frozen three times on liquid nitrogen.
Protein was quantiﬁed by the Bio-Rad protein dye assay reagent (Bio-
Rad, Hercules, CA, USA).
To determine ASYN oligomers, LC3 and acetylated α-tubulin levels
the cytosolic cell extracts were prepared as followed. Individual cell
lines were washed in ice-cold PBS (1×) and lysed in 1% Triton X-100
containing hypotonic lysis buffer (25mM HEPES, pH 7.5, 2mM MgCl2,
1 mM EDTA and 1 mM EGTA supplemented with 2 mM DTT, 0.1 mM
PMSF and a 1:1000 dilution of a protease inhibitor cocktail from
Sigma). Cell suspensions were frozen three times in liquid nitrogen
and centrifuged at 20,000 ×g for 10 min. The resulting supernatants
were removed and stored at−80°C. For the analysis of ASYN oligomers,
the supernatants (Triton-soluble fractions) were collected and saved
and the pellets (Triton-insoluble fractions) were resuspended in 1×
speciﬁc sample buffer (0.2 M Tris–HCl, pH 6.8, 40% glycerol, 2% SDS,
0.005% Coomassie). Protein contentwas determined using Bio-Rad pro-
tein dye assay reagent (Bio-Rad, Hercules, CA, USA).2.10. Live Imaging
After treatment cells were washed with Hanks' balanced salt solu-
tion (HBSS) and incubated with 100nMMitoTracker green (Invitrogen,
Carlsbad, CA) for 30min at 37°C in the dark to label mitochondria [44].
After incubation, cells were carefully washed twice and kept in HBSS.
The cells were then imaged for mitochondrial movements. An organelle
was considered to be no mobile if it remained stationary for the entire
recording period. Movement was counted only if the displacement
was more than the length of the mitochondrion (about 2 μm). Time-
lapse images were captured under a Zeiss LSM 510 meta confocal mi-
croscope with a stage-based chamber (5% CO2, 37°C). The inverted mi-
croscope was driven by LSM software. Images were taken every 2s for a
total of 4 min under 63× magniﬁcation (Zeiss Plan-ApoChromat 63×,
1.4NA). For each time-lapse movie, mitochondria were manually
tracked and transport parameters of mitochondrion movements were
generated using the ImageJ software plug-in Multiple Kymograph, sub-
mitted by J. Rietdorf and A. Seitz (EuropeanMolecular Biology Laborato-
ry, Heidelberg, Germany). Mitochondrial movement velocity data were
determined from the kymographic images and were calculated based
on the slope (v=dx / dt) obtained for each mitochondrion movement
proﬁle along the recording time.Mitochondriawere considered station-
ary if they did not movemore than 2μmduring the entire recording pe-
riod. Each series of images was recorded for at least three randomly
selectedMitotracker Green labelled cells per culture and 3 independent
cultures per condition.
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After treatment cells were washed twice with PBS 1× and ﬁxed for
30 min at room temperature using 4% paraformaldehyde. The ﬁxed
cells were washed again with PBS 1× three times and permeabilized
with 0.2% Triton X-100 for 2 min. Subsequently cells were washed
three times with PBS 1× and blocked with 3% BSA for 30 min. Cells
were then washed again three times with PBS 1× and then incubated
with primary antibody (1:2000 monoclonal anti-α-tubulin from
Sigma (St. Louis, MO, USA) for 1 h; 1:100 polyclonal anti-Tom20 from
Santa Cruz Biotechnology (Santa Cruz, CA., USA) overnight; 1:2000
monoclonal anti-acetylated-α-tubulin from Sigma (St. Louis, MO,
USA) for 1 h; 1:200 polyclonal anti-LC3B from Cell Signaling (Danvers,
MA, USA) overnight; 1:400 rabbit monoclonal anti-LC3 XP® from Cell
Signaling (Danvers, MA, USA); 1:100 anti-LAMP-1 clone H4A3 from
the Developmental Studies Hybridoma Bank (University of Iowa, Iowa
City, IA, USA) overnight; monoclonal anti-βIII-tubulin from Cell Signal-
ing (Danvers, MA, USA) overnight) and then with the appropriate sec-
ondary antibody 1:250 alexa ﬂuor 594 or 1:250 alexa ﬂuor 488 from
Molecular Probes (Eugene, OR, USA). After that cybrid cell lines were
incubated with Hoescth 15 μg/μL for 5 min at RT and protected from
light. Cells were then washed twice in PBS and the coverslips were
immobilized on a glass slide with mounting medium DakoCytomation
(Dako, Glostrup, Denmark). Images were acquired on a Zeiss LSM510
META confocalmicroscope (63× 1.4NAplan-apochromat oil immersion
lens) by using Zeiss LSM510 v3.2 software (Carl Zeiss Inc., Thornwood,
NY, USA) and analyzed using Zeiss LSM Image Examiner. The number
of LC3 dots per cell was quantiﬁed using the “analyze particle” function
of the ImageJ v1.39k (National Institute of Health, USA) program. As
previously described by Dagda and colleagues [45], to quantify two pa-
rameters of mitochondrial morphology an ImageJ macro was used. The
cells stained with Tom20 were extracted to grayscale, inverted to show
mitochondria-speciﬁc ﬂuorescence as black pixels and thresholded to
optimally resolve individualmitochondria. Thismacro tracesmitochon-
drial outlines using “analyze particles”. The area/perimeter ratio was
employed as an index of mitochondrial interconnectivity and inverse
roundness was used as a measure of mitochondrial elongation. Co-
localization between LC3XP/Lamp-1 was quantiﬁed in tresholded
images with the JACoP plug-in of the ImageJ software, according to
Bolte and Cordelières [46].
2.12. Western blot analysis
For the analysis of ASYN oligomers, both fractions (Triton-soluble
and insoluble) were loaded onto 12% SDS-PAGE under non-reducing
and non-denaturating conditions. For the analysis of free and polymer-
ized α-tubulin, acetylatedα-tubulin, LC3B and cytosolic and mitochon-
drial ASYN, the samples were resuspended in 6× sample buffer (4×
Tris.Cl/SDS, pH 6.8, 30% glycerol, 10% SDS, 0,6 M DTT, 0.012%
bromophenol blue). Free and polymerized α-tubulin, as well as,
acetylated-α-tubulin samples were loaded onto 10% SDS-PAGE, LC3B
samples were loaded onto 15% SDS-PAGE, ASYN cytosolic and mito-
chondrial samples were loaded onto 12% SDS-PAGE. All these samples
were loaded under reducing conditions. After the transfer to PVDF
membranes (Millipore, Billerica, MA, USA), the membranes were incu-
bated for 1 h in Tris-Buffered Solution (TBS) containing 0.1% Tween 20Fig. 1.NAP restoresmicrotubule network assembly in PD cells. (A)Western Blot analysis and re
ratio in sPD cybrids. The data show a representative blot of 5 different experiments. Data is rep
(1 nM) prevented the formation of loose tubulin bundles observed in sPD cybrids cells (n= 3)
cation of cells stained as the ones shown here. Data is reported as the fold increase over untrea
NAP (1 nM) promoted a signiﬁcant increase in tubulin acetylation in sPD cybrids. The data show
untreated CT cybrids. (D) Immunocytochemistry of acetylated-α-tubulin showingNAP (1 nM)
intensity was calculated aftermorphometric quantiﬁcation of cells stained as the ones shown he
***p b 0.001, signiﬁcantly differentwhen compared to CT cybrid; #p b 0.05 and###p b 0.001, si
unpaired Student's t-test). All the blots were reprobed for GAPDH to conﬁrm equal protein loaand 5% nonfat milk, followed by an overnight incubation with the re-
spective primary antibodies at 4 °C with gentle agitation: 1:100 mono-
clonal anti-ASYN LB509 from Zymed Laboratories Inc. (South San
Francisco, CA, USA); 1:1000 polyclonal anti-LC3B from Cell Signaling
(Danvers, MA, USA); 1:16,000 monoclonal anti-acetylated α-tubulin
from Sigma (St. Louis, MO, USA); 1:500 polyclonal anti-ubiquitin from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). 1:10,000 monoclonal
anti-α-tubulin from Sigma (St. Louis, MO, USA) was used for the
analysis of free/polymerized α-tubulin and for loading control. 1:500
monoclonal anti-GAPDH from Millipore (Billerica, MA, USA) and 1:100
polyclonal anti-Tom20 from Santa Cruz Biotechnology (Santa Cruz, CA,
USA) were also used for loading control. 1:500 anti-DAT (H80) Santa
Cruz Biotechnology (Santa Cruz, CA, USA) was also used to validate pri-
mary cultures of cortical neurons as a model to study MPP+-induced
toxicity. Membranes were washed with TBS containing 0.1% non-fat
milk and 0.1% Tween three times (each time for 10min), and then incu-
bated with the appropriate horseradish peroxidase-conjugated second-
ary antibody for 2 h at room temperature with gentle agitation. After
three washes, speciﬁc bands of interest were detected by developing
with an alkaline phosphatase enhanced chemical ﬂuorescence reagent
(ECF from GE Healthcare, Piscataway, NJ, USA). Fluorescence signals
were detected using a Biorad Versa-Doc Imager, and band densities
were determined using Quantity One Software.
2.13. Analysis of mitochondrial membrane potential (Δψm) with
rhodamine 123 probe
To monitor changes in mitochondrial membrane potential, rhoda-
mine 123 probe (Rh123) (Molecular Probes, Eugene, OR, USA) was
used. Rh123 is a ﬂuorescent cationic dye that distributes electrophoret-
ically into the mitochondrial matrix in response to the electrical poten-
tial across the inner mitochondrial membrane. The accumulation in
functional mitochondria takes place as a consequence of Rh123 positive
charge; thereby a decrease in Rh123 cellular retention is associatedwith
a decrease in Δψm. Treated cells were washed with PBS (1×) and sub-
sequently loaded in the dark with 1 μM Rh123 in Krebs buffer (pH7.4)
composed of 132 mM NaCl, 4 mM KCl, 1.4 mM MgCl2, 6 mM glucose,
10 mM HEPES, 10 mM NaHCO3, and 1 mM CaCl2. Basal ﬂuorescence
was recorded for 45min at 37 °C (λex=552nm and λem=581 nm).
Afterwards, 1 μM FCCP (protoionophore) and 2 μg/mL oligomycin (in-
hibitor of H+ transporting ATP synthase and an inhibitor of Na+/K+
transporting ATPase) were added to each well in order to achieve max-
imal mitochondrial depolarization and to prevent ATP synthase rever-
sal, respectively. Measurements were recorded for another 15 min at
37°C. Rh123 retention ability was calculated by the difference between
the total ﬂuorescence (after depolarization) and the initial value of ﬂuo-
rescence (basal ﬂuorescence). Results are expressed as a percentage of
the dye retained within the untreated CT cybrids. Measurements were
performed using a Spectramax Plus 384 spectroﬂuoremeter (Molecular
Devices, Sunnyvale, CA, USA).
2.14. MTT cell proliferation assay
Cell proliferation was determined by the colorimetric MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay
(Mosmann, 1983). In viable cells, MTT is metabolized into a formazanspective densitometry showing that NAP (1 nM) decreases the free/polymerizedα-tubulin
orted as absolute values. (B) Immunocytochemistry stainingα-tubulin showing that NAP
. Respective α-tubulin ﬂuorescence intensity was calculated after morphometric quantiﬁ-
ted CT cybrids. (C) Western Blot analysis and respective densitometry demonstrating that
a representative blots of 4 different experiments. Data is reported as the fold increase over
effect on acetylated-tubulin pattern (n= 2). Respective acetylated-α-tubulin ﬂuorescence
re. Data is reported as the fold increase over untreated CT cybrids. *p b 0.05, **p b 0.01 and
gniﬁcantly differentwhen compared to untreated PD cybrid (Bonferroni's t test; two-tailed
ding.
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12 A.R. Esteves et al. / Biochimica et Biophysica Acta 1842 (2014) 7–21that absorbs light at 570nm. Following the cell treatment protocol the
medium was aspirated and 0.5ml MTT (0.5mg/ml) was added to each
well. The plate was then incubated at 37 °C for 3 h. At the end of the
incubation period the formazan precipitates were solubilized with
0.5 ml of acidic isopropanol (0.04MHCl/isopropanol). The absorbance
was measured at 570nm. Cell reduction ability was expressed as a per-
centage of the untreated neurons.
2.15. Data analysis
All data result from the analysis of duplicates per experimental con-
dition in at least three independent experiments and are expressed as
the mean± SEM. Statistical analyses were performed using GraphPad
Prism 5 (GraphPad Software, San Diego, CA, USA). Differences between
two data sets were evaluated by two tailed unpaired Student's t-test.
Statistical tests between multiple data sets and conditions were carried
out using a one way analysis of variance (ANOVA) with pair-wise mul-
tiple comparison procedures using the post hoc Bonferroni's test to
determine statistical signiﬁcance, as appropriate. A p-value b 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. NAP rescues mitochondrial-mediated microtubule network disruption
Microtubule assembly requires a balanced equilibrium between
polymerized and unpolymerized tubulin. We assessed NAP (1 nM)
effect on microtubule network through immunoblotting and mea-
surement of the levels of free and polymerized α-tubulin. We ob-
served that NAP signiﬁcantly decreased the ratio between free and
polymerized tubulin in sPD cybrids comparatively to untreated sPD
cybrids (p b 0.001) (Fig. 1A), and induced the formation of tubulin
bundles similar to those observed in untreated CT cybrids cells
(Fig. 1B). Subsequently we evaluated α-tubulin acetylation levels,
since this post-translational modiﬁcation is a marker of stablemicro-
tubules [47]. Interestingly, NAP promoted a signiﬁcant increase in α-
tubulin acetylation levels in sPD cybrids indicating that it promotes
microtubule stability (p b 0.05) (Fig. 1C). These results were con-
ﬁrmed by immunocytochemistry analysis of acetylated-α-tubulin
levels showing that sPD cybrids harbor less acetylated-α-tubulin
levels and that NAP promoted an increase in the acetylation of α-
tubulin.
In order to prove that NAP targets the microtubule systemwe quan-
titatively evaluated whether NAP prevented the disruption of the mi-
crotubule network promoted by nocodazole. We observed that NAP
prevented microtubule depolymerization induced by nocodazole
(Figs. S1A, B), decreasing the ratio between free and polymerized α-
tubulin and increasing acetylated α-tubulin levels (p b 0.01). Interest-
ingly, despite nocodazole induced an overall decrease in the levels of
acetylatedα-tubulin (Fig. S1B) it also induced the formation of acetylat-
edα-tubulin knots in both CT and sPD cybrids (Data not shown). These
results corroborate and extendprevious observation in primary cultures
derived from rat cerebral cortex [48].
3.2. NAP positively affects mitochondrial trafﬁcking
Mitochondrial long-distance transport, to reach all the places that
need energy, is mainlymediated bymotor proteins powered by ATP hy-
drolysis that shuttle mitochondria along microtubules [49]. We have
shown earlier that mitochondrial deﬁcits induce alterations in microtu-
bule network, mainly characterized by an increase in free/polymerized
tubulin ratio [50] and by an impairment of mitochondrial trafﬁcking
[40]. In order to determine if NAP could improve intracellular trafﬁcking
we recordedwhether mitochondria moved or remained static (Fig. 2A),
and subsequently the moving mitochondrion velocity (Fig. 2B) and
the relative number of stationary or movable events were calculated(Fig. 2C), as previously described [40]. Accordingly to our previous re-
sults, average mitochondrial velocities were decreased in sPD cybrids.
As expected, NAP promoted an increase in movingmitochondria veloc-
ity in sPD cybrids (Fig. 2B), despite no signiﬁcant change is reached. As
shown in Fig. 2C, sPD cybrids exhibited a signiﬁcant decreased number
of movable mitochondria in the studied ﬁelds. In addition, NAP was
able to reestablish the number of movable mitochondria in sPD cybrid
cells. Altogether, our data suggest that promoting the dynamic stability
and functional integrity of microtubule network allows mitochondrial
motility.3.3. NAP restores microtubule dependent trafﬁc allowing macroautophagy
completion
Autophagic ﬂux is highly dependent on microtubule network. In
fact, microtubules have been implicated in the initiation and matura-
tion of autophagosomes, serve as tracks for movement of mature
autophagosomes and bring autophagosomes and lysosomes together
for fusion and disposal of autophagosomal cargo [51,52]. Therefore,
we decided to explore NAP effects on the autophagic pathway in our
cellular model, since previous data showed that LC3II levels are in-
creased in sPD cybrids when compared to CT cybrids indicating that
sPD cybrids either harbor decreased autophagosomal biogenesis or
decreased autophagosomal degradation [40]. To address this question
we monitored the autophagic ﬂux, the process from autophagosome
formation to degradation, comparing the accumulation of auto-
phagosomes after inhibition of lysosomal function (with NH4Cl and
leupeptin) to the steady-state levels. Interestingly, when we treated
cells with NAP, LC3II content decreased (pb0.01) (Fig. 3A) and the au-
tophagic ﬂux increased in sPD cybrids compared to untreated sPD
cybrids (Fig. 3B) (pb0.001). Additionally, these data were corroborat-
ed by LC3B staining where we observed a reduction in the number of
LC3B dots in NAP-treated sPD cybrids when compared to untreated
sPD cybrids (Fig. 3C, D). Remarkably, NAP by modulating microtubule-
dependent trafﬁc of autophagosomes was effective in promoting
autophagy turnover in sPD cybrids, as reﬂected by the decreased
autophagosome content and improved autophagic ﬂux. These ﬁnd-
ings suggest that the dynamic interaction of autophagic vacuoles
with the microtubule system tracks are altered in sPD cybrids,
which obstructs autophagosome transport and so the fusion with ly-
sosome. Autophagosome–lysosome fusion can be visualized via im-
munoﬂuorescence imaging as the co-localization of LC3B positive
vesicles with a lysosome marker (e.g., LAMP-1) [53]. We observed a
decreased degree of co-localization between LC3B positive vacuoles
and Lamp-1 positive vacuoles in sPD cybrids, an effect that was re-
versed by NAP treatment (Fig. 3E, F). This result indicates that
macroautophagy is not concluded in sPD cybrids due to a disruption
in the autophagosomal intracellular trafﬁc and not to an impairment
of autophagosome–lysosome fusion. As a control we used a known
autophagic inducer (rapamycin) and found that in sPD cybrids,
rapamycin did not improve autophagic ﬂux indicating that although
autophagy is being induced, sPD cybrids are unable to efﬁciently pro-
ceed with the pathway probably due to vesicular trafﬁc impairment
(Fig. S2).
Similar to autophagosomes, ASYN is actively transported by
microtubules from its site of synthesis in the cell body along the
axons to synaptic termini. Several data indicated that defective axo-
nal transport of ASYN is a potential pathogenic event in alpha-
synucleinopathies [54,55]. We observed that NAP signiﬁcantly
reduced both ASYN Triton-soluble low weight oligomers and
Triton-insoluble high weight oligomer accumulation (p b 0.05)
(Fig. S3). These ﬁndings suggest that NAP by improving microtubule-
dependent trafﬁc additionally improves autophagic efﬁciency to clear
speciﬁc substrates such as aggregated ASYN or/and reduces ASYN pro-
pensity to oligomerize.
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Fig. 2.NAP improvesmitochondrial trafﬁcking in PDcells. (A) Representative kymograph images ofmitochondrialmovement inCT and PD cybrid cells treatedwithNAP (1nM). Scale bars:
5 μM. (B) Averagemitochondria trafﬁcking velocity (μm/s) shows that NAP slightly increases sPD cybridmitochondrial movements (n=5). (C) A number ofmovablemitochondria were
compared with those of total mitochondria indicating that NAP increases the number of movable mitochondria in sPD cybrids (n=5). The data is a representative of 5 experiments with
duplicated samples. *pb0.05 signiﬁcantly differentwhen compared to CT cybrid; #pb0.05 signiﬁcantly different when compared to untreated sPD cybrids. (Bonferroni's t test; two-tailed
unpaired Student's t-test).
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Our next goal was to evaluate the NAP effect on mitochondria
dynamics and function. We previously observed that NAP improved
mitochondrial trafﬁcking (Fig. 2), therefore we ﬁrst addressed mito-
chondrial distribution, elongation and interconnectivity by using
Tom20 antibody staining [56–61]. Tom20 is a subunit of the TOM
(translocase of outer membrane) receptor complex responsible for the
recognition and translocation of cytosolically synthesizedmitochondrial
pre-proteins [62]. We visualized that in sPD cybrids, mitochondrial dis-
tributionwasmore perinuclear than in CT cybridswhich is in agreement
with the impairment inmitochondrial trafﬁcking (Fig. 4A). Interestingly,
we observed a decrease in themitochondrial network in sPD cybrids rel-
atively to CT cybrids, which was reverted after NAP exposure. In fact,
NAP improved the mitochondrial interconnectivity in sPD cybrids
(Fig. 4B). Mitochondrial interconnectivity is calculated as the meanarea/perimeter ratio and is consistent with the degree of mitochondrial
branching, namely the connectivity/dynamics between mitochondria.
Worthy of notice is that in NAP-treated cybrids, mitochondria seemed
more elongated than in untreated cybrids (Fig. 4A, C). On the other
hand, nocodazole exposure increased the mitochondrial fragmentation
in sPD cybrids and in both cybrids decreased themitochondrial elonga-
tion (Fig. 4A, C).
We next assessed the mitochondrial function after NAP treatment.
Consistent with our previous data we observed a loss of mitochondrial
membrane potential in sPD cybrids comparatively to CT cybrids
(pb0.05) (Fig. 4D) [18]. Recent work has shown that parkin selectively
and rapidly translocates from the cytosol to depolarized mitochondria,
where it mediates the ubiquitination of mitochondrial substrates,
such as, voltage-dependent anion-selective protein 1 (VDAC1) and
mitofusins 1 and 2 [63–65], promoting mitochondrial ﬁssion. There-
fore an increase in mitochondrial ubiquitination can also indicate
14 A.R. Esteves et al. / Biochimica et Biophysica Acta 1842 (2014) 7–21that mitochondria are being fragmented in order to be targeted for
degradation (mitophagy). Correlated with a decrease in mitochondri-
al membrane potential we also observed an increase in mitochondrial0.00
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(pb0.05 and pb0.001, respectively) (Fig. 4D, E). We also examined mi-
tochondrial ASYN sequestration since several reports have conﬁrmed
ASYN localization into the mitochondria [66–68]. We detected an in-
crease in ASYN mitochondrial accumulation in sPD cybrids relatively
to CT cybrids, which was reduced by NAP treatment (Fig. 4F). Our re-
sults support the idea that NAP, by promoting autophagic vacuole clear-
ance, allows the elimination of damaged mitochondria and maintains
the pool of healthy mitochondria.
3.5. The MPP+ model: veriﬁcation of the results
To extend the above ﬁndings and further conﬁrm our previous ob-
servation that mitochondrial deﬁcits can compromise the degradative
ability of the autophagic system, we used primary cortical neurons
treated with MPP+, an in vitromodel of PD, which associates neuronal
dysfunction with mitochondrial and microtubule impairments [69,70].
We show that primary cortical neurons (rat embryo neocortex) express
dopamine transporter (DAT) (SFig. 4A) and that MPP+ reduces mito-
chondrial dehydrogenase activity (SFig. 4B) and induces a decrease in
mitochondrial membrane potential in neurons (SFig. 4C). Nevertheless,
it was also demonstrated that MPP+ directly impaired microtubules
in neuronal cells [70]. In our model, we have also found a decrease in
α-tubulin acetylation levels (p b 0.01) that was slightly prevented by
NAP (10 nM) treatment (Fig. 5A). Moreover, in this acute model we
have also found a rapid accumulation of LC3II within 4h after blocking
of lysosomal proteolysis, indicating a constitutive autophagic ﬂux in
primary cortical neurons (Fig. 5B). However, we could not observe an
increase in the number of LC3II in MPP+-treated cells when compared
to control cells (Fig. 5B), although this was accompanied by a signiﬁcant
reduction on the autophagic ﬂux (pb0.01) (Fig. 5B, C), similar to the re-
sults obtained in sPD cybrids. NAP was able to restore the autophagic
ﬂux impaired by MPP+-treatment (p b 0.05) (Fig. 5B, C). βIII-Tubulin
staining also indicated a decrease in the length and number of neuronal
processes after MPP+ exposure that are restored by NAP treatment,
indicating an increase in neuronal viability and plasticity. Moreover,
MPP+-treated neurons show a less distributed mitochondrial network
when compared to untreated neurons (Fig. 5D). NAP improved not
only the microtubular network but also the mitochondrial distribution
and interconnectivity. Althoughwithminor differences between chron-
ic and acutemodels, together these data suggest that mitochondrial im-
pairment leads to alterations in the autophagy system, as mainly
translated by a reduction in the autophagic ﬂux and that this is due to
alterations in microtubule-dependent trafﬁc.
4. Discussion
In this study we show that the repair of microtubule assembly
prevents the accumulation of PD neuropathological hallmarks in
cells with mitochondrial deﬁcits. We present evidence that NAP, a
microtubule stabilizing peptide, improves microtubule network as-
sembly and so boosts mitochondrial trafﬁcking and autophagic
ﬂux, restores mitochondrial membrane potential and reduces ASYN
oligomers accumulation.Fig. 3.NAPpromotes autophagic clearance in PD cells. (A) Immunoblot for endogenous LC3B fro
and Leupeptin, N/L) and respective quantiﬁcation of autophagic vacuole (AV) levels. Values of LC
α-tubulin to conﬁrm equal protein loading. The data show a representative blot derived from 5
(B) Assessment of autophagic ﬂux, calculated as the ratio of LC3II densitometric value of N/L
showed an increase in autophagic ﬂux. Data is reported as the fold increase over untreated CT
NAP-treated sPD cybrids when compared to untreated sPD cybrids (n = 2). Scale bars: 20 μ
cells stained as the ones shown here. Data is reported as absolute values. (E) LC3B (green) an
last 4 h, cells were co-treated with or without lysosomal inhibitors (N/L) (n = 2). Scale bars:
localization between LC3B and Lamp-1 (G) Lamp-1 ﬂuorescence intensity was calculated after
absolute values. *pb 0.05, **p b 0.01 and *** p b 0.001, signiﬁcantly different when compared to
to untreated PD cybrid. &p b 0.05, signiﬁcantly different when compared to PD cybrid treated wSeveral studies place mitochondrial dysfunction as the triggering
event leading to the subsequent pathological hallmarks in PD [71].
Moreover, microtubule disorganization has also been shown to occur
in PD. Indeed, two mitochondrial toxins widely used to model PD
have been shown to affect microtubule dynamics [72–74]. Previous
work from our group demonstrated that sPD cybrids with a complex I
defect, ATP depletion and loss of mitochondrial membrane potential
[18] have a disorganized microtubule network [22]. An impaired
microtubule-dependent trafﬁc can compromise themovement of mito-
chondria, protein aggregates and autophagic vacuoles. This will in turn
contribute to an accumulation of autophagosomes, defective mitochon-
dria and protein oligomers leading to cell toxicity. In fact, in our previ-
ous work we also observed that ASYN oligomers accumulate in PD
cybrids [22].
Herein, our major goal was to assess if the modulation of microtu-
bule network could be a feasible therapeutic target to PD. For this pur-
pose we used an ex-vivo model, CT and sPD cybrids that share the
same nuclear background but different mitochondrial background and
an in-vitro model, cortical neurons exposed to MPP+, a metabolite of
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine that was shown to in-
duce Parkinsonism in humans, primates, and mice [1].
To modulate microtubule network, we used NAP (1 nM in cybrid
cells and 10nM in cortical neurons exposed to MPP+), an eight amino
acid peptide, derived from activity-dependent neuroprotective protein,
amolecule that is essential for brain formation [75,76]. The fundamental
mechanism for NAP protection is its interaction with the microtubule
cytoskeleton, protectingmicrotubule function. In fact, NAP preferential-
ly interacts with neuronal and glial tubulin and enhances proper micro-
tubule assembly leading to increased cellular survival [77]. Despite
previous data demonstrated that Epothilone D and taxol, two known
antitumor drugs used to ﬁght cancer, can be used as a neuroprotective
strategy in Alzheimer's and Parkinson's disease models [22,78,79] we
choose NAP peptide because it penetrates cells and crosses the blood-
barrier after nasal or systematic administration, which makes it into a
promising therapeutic molecule [80]. NAP has been shown to provide
neuroprotection, in vivo and in vitro in several disease models [81–83]
including Alzheimer's disease models [84–87]. Intranasal administra-
tion of NAP in mice overexpressing ASYN, improved motor function
and reduced ASYN pathology [88]. Mechanistically, NAP was shown to
preventmitochondrial cytochrome c release in parallel with the protec-
tion of the microtubule network [89], connecting mitochondrial func-
tion to microtubule assembly as observed here.
Microtubules are highly stable and post-translational modiﬁcations
such as acetylation of α-tubulin play a role in the maintenance of
stable populations of microtubules [90,91]. Accordingly, we observed a
decrease inα-tubulin acetylation in sPD cybrids, which indicatesmicro-
tubule instability. Most interestingly, we found that NAP increased the
α-tubulin acetylation levels thereby improving microtubule assembly.
These results were further conﬁrmed in cortical neurons where α-
tubulin acetylation decreased after MPP+ exposure and was reversed
following NAP treatment. Microtubular acetylation has been shown to
cause the recruitment of molecular motor dyneins and kinesins to
microtubules therefore possessing a role not only for the kinesin-
dependent anterograde trafﬁcking but also for the dynein-dependentmCT and PD cybrids treatedwith NAP (1nM)with orwithout lysosomal inhibitors (NH4Cl
3II in the absence of N/L represent the steady state AV content. The blotswere reprobed for
independent experiments. Data is reported as the fold increase over untreated CT cybrids.
treated samples over the corresponding untreated samples. NAP-treated PD cybrid cells
cybrids. (C) Immunocytochemistry analysis of LC3B showing a reduction in LC3B dots in
m. (D) LC3B ﬂuorescence intensity was calculated after morphometric quantiﬁcation of
d Lamp-1 (red) immunostaining of CT and sPD cybrids treated with NAP for 24 h. In the
20 μm. (F) Assessment of LC3B and Lamp-1 co-localization. Data is reported as % of co-
morphometric quantiﬁcation of cells stained as the ones shown here. Data is reported as
untreated CT cybrid; #pb 0.05, and ### p b 0.001, signiﬁcantly different when compared
ith NAP. (Bonferroni's t test; two-tailed unpaired Student's t-test).
(A)
Blue Hoescht; Green Tom20
(B)
(C)
0
1
2
3
4 CT cybrids
ct NAP Noc ct NAP Noc
PD cybrids
**
###
*** ##
M
ito
ch
on
dr
ia
l E
lo
ng
at
io
n
0.00
0.05
0.10
0.15 CT cybrids
PD cybrids
ct NAP Noc ct NAP Noc
###
**
M
ito
ch
on
dr
ia
l
In
te
rc
on
ne
ct
iv
ity
(E)
0.0
0.5
1.0
1.5
Basal NAP
CT cybrids
PD cybrids
citosol citosol citosol citosol mitomitomitomito
*
#
Al
ph
a-
sy
nu
cle
in
 o
lig
om
er
s 
co
nt
en
t
(re
lat
ive
 to
 cy
tos
oli
c b
as
al 
CT
 cy
bri
ds
)
(D)
0
50
100
150
ct ctNAP NAP
CT cybrids
PD cybrids
*
#
R
ho
da
m
in
e 
12
3 
re
te
nt
io
n
(%
 of
 co
ntr
ol)
(F)
Basal Nocodazole NAP
CT
 
cy
br
id
PD
 
cy
br
id
0
1
2
3
4
5
cytosol cytosol cytosol cytosolmito mito mito mito
Basal NAP
CT cybrids
***
***
# PD cybrids
M
ito
ch
on
dr
ia
l a
nd
 C
yt
os
ol
ic
u
bi
qu
itin
at
io
n 
co
nt
en
t
(re
lat
ive
 to
 ba
sa
l c
yto
so
lic
 C
T c
yb
rid
)
cytosol mito cytosol mito cytosol mito cytosol mito
75kDa
50kDa
37kDa
100kDa
150kDa
250kDa
25kDa
CT cybrid
Untreated NAP
CT cybrid PD cybridPD cybrid
20kDa Tom20
50kDa 
Alpha-tubulin
20kDa Tom20
50kDa 
Alpha-tubulin
cytosol mito cytosol mito cytosol mito cytosol mito
CT cybrid
Untreated NAP
CT cybrid PD cybridPD cybrid
75kDa
50kDa
37kDa
100kDa
150kDa
250kDa
25kDa
χ
ϕ
ϕ
ϕ
16 A.R. Esteves et al. / Biochimica et Biophysica Acta 1842 (2014) 7–21
17A.R. Esteves et al. / Biochimica et Biophysica Acta 1842 (2014) 7–21retrograde trafﬁcking of either lysosomes or autophagosomes [92,93].
Recent work from Xie and colleagues revealed that acetylated microtu-
bules are required for the fusion of autophagosomes with lysosomes
[94]. Hence NAP, by increasing α-tubulin acetylation, can also promote
the fusion of autophagosomes and lysosomes and subsequently im-
prove autophagic degradation of its substrates. Indeed, we observed
that NAP increased autophagosome–lysosome fusion in sPD cybrids.
Besides, autophagosomes that move along microtubules, facilitate
autophagosome formation and are required to direct dispatch auto-
phagosomes for degradation [51,52]. Nocodazole, a knownmicrotubule
depolymerizing agent, was shown to inhibit lysosome fusion with
autophagosomes resulting in an inefﬁcient degradation of autophagic
substrates [95]. Here, NAP protected against nocodazole-induced mi-
crotubule disassembly, corroborating and extending previous observa-
tions [48]. In our previous work we observed that LC3II levels were
increased in sPD cybrids relatively to CT cybrids and that this was due
to reduced rate of LC3II-associated autophagosomes clearance [40].
Given the fact that microtubules are responsible for axonal transport
of organelles and vesicles, we decided to study whether NAP, by pro-
moting microtubules assembly, probably due to increasing α-tubulin
acetylation, would also restore the autophagic ﬂux, so potentiating
autophagosomal degradation. We observed that NAP promoted
autophagosomal clearance in sPD cybrids comparatively to untreated
sPD cybrids. Additionally, we observed an increase in autophagic ﬂux
in MPP+-exposed neurons after NAP treatment, which supports our
cybrid data. Interestingly, rapamycin, a classic activator of autophagy,
was not able to increase the autophagic ﬂux in sPD cybrids despite an
increase in LC3II levels. These results further corroborate that autopha-
gic induction is not compromised in sPD cybrids cells and that auto-
phasosomal clearance failure is due to a defect in the microtubule-
dependent intracellular trafﬁc. Moreover, our previous results showed
that rapamycin-induced autophagy did not prevent caspase-3 activa-
tion in sPD cybrids showing no protective effect [40].
Mitochondria are one of the main substrates for autophagy [96] and
recent works have linked defects in mitophagy to PD. Parkin and Pink1,
two genes that are mutated in autosomal recessive PD, have been
shown to play a role in mitophagy. Pink1, a mitochondrial kinase
known to function upstream of parkin, accumulates in dysfunctional
mitochondria upon loss of mitochondrial membrane potential, and
this accumulation leads to mitochondrial parkin recruitment. Parkin
once in the mitochondria triggers the assembly of p62 onto mitochon-
dria by ubiquitination of VDAC1 and promotes mitochondrial ﬁssion
by ubiquitination of mitofusins [63,59,97]. Eventually, after fragmenta-
tion of the mitochondrial pool, damaged mitochondria are surrounded
selectively by autophagosomal membrane via p62–LC3 interaction
[64]. Indeed we observed an increase in mitochondrial fragmentation
in our sPD cybrids and in MPP+-treated neurons. Despite this, a
sustained increase in mitochondrial protein ubiquitination levels and a
decrease in mitochondrial membrane potential are still observed in
our sPD cells. We correlate these observations with the reduction of au-
tophagic ﬂux that do not allow for the removal of damaged mitochon-
dria, despite the activation and formation of autophagosomes. It hasFig. 4.NAP improvesmitochondrial function through completion of autophagy. (A) Immunocyto
and ameliorates mitochondrial distribution (n= 3). Mitochondrial morphology was calculated
(B) Mitochondrial interconnectivity and (C) mitochondrial elongation was assessed using an Im
dition per experiment. **pb0.01, *** pb0.001 signiﬁcantly differentwhen compared to untreate
sPD cybrids (Bonferroni's t test). (D)Mitochondrial membrane potential was expressed as the p
SEM derived from 5 independent experiments.*pb0.05, signiﬁcantly different when compared
cybrids (Bonferroni's t test). (E) Western Blot analysis and respective densitometry of ubiquit
cybrids in both cytosolic and mitochondrial fractions. Mitochondrial and cytosolic fractions w
Blots are representative of 3 experiments. Data is reported as the fold increase over untreated
cytosolic fraction;#pb0.05, signiﬁcantly differentwhen compared to untreated CT cybridmitoc
cytosolic fraction; χp b 0.05, signiﬁcantly different when compared to untreated PD cybrid m
cytosolic ASYN content, showing a reduction of both cytosolic and mitochondrial ASYN conten
for Tom20 andα-tubulin respectively in order to conﬁrm fraction purity. Blots are representativ
*p b 0.05, signiﬁcantly different when compared to untreated CT cybrid cytosolic fraction; #p
φp b 0.05, signiﬁcantly different when compared to untreated PD cybrid mitochondrial fractionbeen described that a failure in mitochondrial trafﬁcking, similar to
what we observed in sPD cybrids, induces a mitochondrial perinuclear
distribution and an increase in mitochondrial fragmentation [98,99].
Interestingly, we observed that in the sPD cybrids, NAP restored mito-
chondrial trafﬁcking and distribution and promoted mitochondrial
elongation and interconnectivity. Further validating this data we also
observed that NAP promoted the assembly of βIII-tubulin network, as
well as, mitochondrial distribution and interconnectivity in MPP+-
treated cortical neurons. Gomes and co-workers reported that elongat-
edmitochondria possessmore cristae and increasedATP synthase activ-
ity, allowing the maintenance of ATP levels [100]. NAP, by improving
tubulin-dependent trafﬁc facilitates damaged mitochondria clearance
by autophagy,which potentiates themaintenance of a healthymitochon-
drial pool.Moreover,mitochondrial distribution and recruitment to local-
ized areaswith increased energy or calciumbuffering requirementsmake
mitochondrial movement an important ongoing and regulated process
[101,102]. In our work mitochondrial deﬁcient cells show a decrease in
mitochondrialmovement thatwas abolished byNAP treatment.More in-
terestingly, we found that NAP decreases mitochondrial ubiquitination,
restores mitochondrial membrane potential in sPD cybrids and reduces
mitochondrial ASYN accumulation in sPD cybrids suggesting that dam-
agedmitochondria are being cleared by autophagy. These results, togeth-
er with the fact that NAP elongates mitochondria, show that NAP by
recoveringmicrotubule dependent trafﬁc efﬁciently start a positive feed-
back loop where damaged mitochondria are degraded, healthy mito-
chondria survive and mitochondrial normal metabolism is restored.
ASYN is degraded by both autophagy and proteasome [103]. Howev-
er, ASYN oligomers block both chaperone mediated autophagy and
proteosomal function. So, in situations where ASYN undergoes post-
translational modiﬁcations, is oxidized or oligomerized, it can only be
degraded by macroautophagy [104–107]. Furthermore, transport of
ASYN requires an intact microtubule network and involves kinesin and
dynein motor proteins. [108]. Li and colleague's results indicated that
ASYN transport slows with aging [54]. This may lead to longer half-life
of ASYN allowing greater opportunities for aggregation-promotingmod-
iﬁcations, such as protein oxidation [109–111,19]. Therefore, the age-
associated changes in ASYN transport may contribute to the axonal
ASYN abnormalities associatedwith alpha-synucleinopathies. Our previ-
ous work showed that microtubule destabilization driven by mitochon-
drial damage and deﬁcient ATP supply leads to ASYN oligomerization
[22]. Herein we demonstrate that NAP-treated cybrids have a reduction
in ASYN oligomers, which is probably due to their degradation, either
alone or together with mitochondria by autophagy. Moreover, the
enhancement of ASYN trafﬁc diminishes ASYN monomers opportunity
to react with ROS [19] or calpains [50] reducing its capacity to
oligomerize and to accumulate. Indeed, NAP also reducesmitochondrial
ASYN accumulation showing that ASYN sequestered bymitochondria is
cleared by mitophagy or ASYN probability to oligomerize and to be
sequestered by mitochondria is reduced.
In this work, we show strong evidence that by inducing microtu-
bule assembly we can protect PD cells from ASYN accumulation and
damaged mitochondria deleterious effects. Thus, by recovering thechemistry analysis of Tom20 showing thatNAP (1nM) restoresmitochondrion elongation
after morphometric quantiﬁcation of cells stained with Tom20 as the ones shown here.
ageJ macro. Data is reported as absolute values. N=3with 10–20 cells analyzed per con-
d CT cybrids; ##pb0.01, ###pb0.001, signiﬁcantly differentwhen compared to untreated
ercentage of rhodamine 123 retention relatively to untreated CT cybrids, with themean±
to untreated CT cybrids; #pb0.05, signiﬁcantly different when compared to untreated sPD
inated protein levels illustrating a decrease of total ubiquitin content in NAP-treated sPD
ere reprobed for Tom20 and α-tubulin, respectively in order to conﬁrm fraction purity.
CT cybrids. *** p b 0.001, signiﬁcantly different when compared to untreated CT cybrid
hondrial fraction;φφpb0.01, signiﬁcantlydifferentwhen compared to untreated PDcybrid
itochondrial fraction. (F) Western Blot analysis and densitometry of mitochondrial and
t after NAP treatment in sPD cybrids. Mitochondrial and cytosolic fractions were reprobed
e of 6 different experiments. Data is reported as the fold increase over untreated CT cybrids.
b 0.05, signiﬁcantly different when compared to untreated PD cybrid cytosolic fraction;
. (Bonferroni's t test; two-tailed unpaired Student's t-test).
18 A.R. Esteves et al. / Biochimica et Biophysica Acta 1842 (2014) 7–21autophagicﬂux a subsequent reduction in ASYN oligomer accumulation
and a decrease in damaged mitochondria build-up occur. Therefore,
NAP demonstrates a great potential to treat neurodegenerative disease
like PD, hampering the appearance of typical pathological hallmarks. In(A)
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